Treatment of myelodysplastic syndromes with orally administered 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate.

Abstract

1-beta-D-Arabinofuranosylcytosine-5'-stearylphosphate (fosteabine) was administered orally to patients with myelodysplastic syndromes (MDS); refractory anemia with excess of blasts (RAEB), RAEB in transformation, acute leukemia derived from RAEB and chronic myelomonocytic leukemia, in an early phase II study in a multi-institutional study. Among 62 evaluable patients, 2 patients achieved a complete remission, 6 a good response and 8 partial response by daily oral administration of 100-200 mg of fosteabine. The overall response rate was 25.8%. The response rates were almost the same among the four subtypes of MDS. Responses were reached 2-23 weeks (median, 8 weeks) after the start of therapy and continued for 3-50 weeks (median, 10 weeks). Major side effects were myelosuppression and gastrointestinal toxicities. In spite of the disadvantages, such as unpredictable absorption, this newly developed orally administrable cytarabine analogue will be a useful drug in the treatment of MDS.

• Authors: R Ohno, N Tatsumi, M Hirano, K Imai, H Mizoguchi, T Nakamura, M Kosaka, K Takatsuki, T Yamaya, K Toyama
• Journal: Oncology (Oncology) Vol. 48 Issue 6 Pg. 451-5 ( 1991) ISSN: 0030-2414 [Print] Switzerland
• PMID: 1749580 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Arabinonucleotides
• 1-arabinofuranosylcytosine-5'-stearylphosphate
• Cytidine Monophosphate

Topics

• Adult
• Aged
• Aged, 80 and over
• Arabinonucleotides (adverse effects, therapeutic use)
• Cytidine Monophosphate (adverse effects, analogs & derivatives, therapeutic use)
• Dose-Response Relationship, Drug
• Drug Evaluation
• Female
• Humans
• Male
• Middle Aged
• Myelodysplastic Syndromes (drug therapy)